Literature DB >> 23430613

Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention.

Amarylis Wanschel1, Tara Seibert, Bernd Hewing, Bhama Ramkhelawon, Tathagat D Ray, Janine M van Gils, Katey J Rayner, Jonathan E Feig, Edward R O'Brien, Edward A Fisher, Kathryn J Moore.   

Abstract

OBJECTIVE: The persistence of myeloid-derived cells in the artery wall is a characteristic of advanced atherosclerotic plaques. However, the mechanisms by which these cells are retained are poorly understood. Semaphorins, a class of neuronal guidance molecules, play a critical role in vascular patterning and development, and recent studies suggest that they may also have immunomodulatory functions. The present study evaluates the expression of Semaphorin 3E (Sema3E) in settings relevant to atherosclerosis and its contribution to macrophage accumulation in plaques. APPROACH AND
RESULTS: Immunofluorescence staining of Sema3E, and its receptor PlexinD1, demonstrated their expression in macrophages of advanced atherosclerotic lesions of Apoe(-/-) mice. Notably, in 2 different mouse models of atherosclerosis regression, Sema3E mRNA was highly downregulated in plaque macrophages, coincident with a reduction in plaque macrophage content and an enrichment in markers of reparative M2 macrophages. In vitro, Sema3E mRNA was highly expressed in inflammatory M1 macrophages and in macrophages treated with physiological drivers of plaque progression and inflammation, such as oxidized low-density lipoprotein and hypoxia. To explore mechanistically how Sema3E affects macrophage behavior, we treated macrophages with recombinant protein in the presence/absence of chemokines, including CCL19, a chemokine implicated in the egress of macrophages from atherosclerotic plaques. Sema3E blocked actin polymerization and macrophage migration stimulated by the chemokines, suggesting that it may immobilize these cells in the plaque.
CONCLUSIONS: Sema3E is upregulated in macrophages of advanced plaques, is dynamically regulated by multiple atherosclerosis-relevant factors, and acts as a negative regulator of macrophage migration, which may promote macrophage retention and chronic inflammation in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23430613      PMCID: PMC3647027          DOI: 10.1161/ATVBAHA.112.300941

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  45 in total

Review 1.  Semaphorins and their receptors in vertebrates and invertebrates.

Authors:  J A Raper
Journal:  Curr Opin Neurobiol       Date:  2000-02       Impact factor: 6.627

Review 2.  Molecular basis of semaphorin-mediated axon guidance.

Authors:  F Nakamura; R G Kalb; S M Strittmatter
Journal:  J Neurobiol       Date:  2000-08

3.  Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients.

Authors:  M Janabi; S Yamashita; K Hirano; N Sakai; H Hiraoka; K Matsumoto; Z Zhang; S Nozaki; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-08       Impact factor: 8.311

4.  Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice.

Authors:  Eugene Trogan; Robin P Choudhury; Hayes M Dansky; James X Rong; Jan L Breslow; Edward A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

5.  Increased prevalence of semaphorin 3C, a repellent of sympathetic nerve fibers, in the synovial tissue of patients with rheumatoid arthritis.

Authors:  Luitpold E Miller; Claudia Weidler; Werner Falk; Peter Angele; Jens Schaumburger; Jürgen Schölmerich; Rainer H Straub
Journal:  Arthritis Rheum       Date:  2004-04

6.  Mouse model of heterotopic aortic arch transplantation.

Authors:  Igor Chereshnev; Eugene Trogan; Sabina Omerhodzic; Vitalii Itskovich; Juan-Gilberto Aguinaldo; Zahi A Fayad; Edward A Fisher; Ernane D Reis
Journal:  J Surg Res       Date:  2003-05-15       Impact factor: 2.192

7.  Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques.

Authors:  Jaime Llodrá; Véronique Angeli; Jianhua Liu; Eugene Trogan; Edward A Fisher; Gwendalyn J Randolph
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-27       Impact factor: 11.205

8.  Semaphorin 3E/collapsin-5 inhibits growing retinal axons.

Authors:  Karin Steinbach; Hansjürgen Volkmer; Burkhard Schlosshauer
Journal:  Exp Cell Res       Date:  2002-09-10       Impact factor: 3.905

9.  Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome.

Authors:  Jonathan E Feig; Yuliya Vengrenyuk; Vladimir Reiser; Chaowei Wu; Alexander Statnikov; Constantin F Aliferis; Michael J Garabedian; Edward A Fisher; Oscar Puig
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

10.  CC chemokine receptor (CCR)2 is required for langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, b cell outgrowth, and sustained neutrophilic inflammation.

Authors:  N Sato; S K Ahuja; M Quinones; V Kostecki; R L Reddick; P C Melby; W A Kuziel; S S Ahuja
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

View more
  49 in total

Review 1.  Macrophages in atherosclerosis: a dynamic balance.

Authors:  Kathryn J Moore; Frederick J Sheedy; Edward A Fisher
Journal:  Nat Rev Immunol       Date:  2013-09-02       Impact factor: 53.106

Review 2.  Potential contributions of intimal and plaque hypoxia to atherosclerosis.

Authors:  Guo-Hua Fong
Journal:  Curr Atheroscler Rep       Date:  2015-06       Impact factor: 5.113

Review 3.  Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2).

Authors:  Kathryn J Moore; Simon Koplev; Edward A Fisher; Ira Tabas; Johan L M Björkegren; Amanda C Doran; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2018-10-30       Impact factor: 24.094

Review 4.  Semaphorins and plexins as therapeutic targets.

Authors:  Thomas Worzfeld; Stefan Offermanns
Journal:  Nat Rev Drug Discov       Date:  2014-08       Impact factor: 84.694

5.  Semaphorin-3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11C+ and CD4+ CD25- T-cells.

Authors:  Laëtitia Kermarrec; Nour Eissa; Hongxing Wang; Kunal Kapoor; Abdoulaye Diarra; Abdelilah S Gounni; Charles N Bernstein; Jean-Eric Ghia
Journal:  Br J Pharmacol       Date:  2019-04-01       Impact factor: 8.739

Review 6.  Netrins & Semaphorins: Novel regulators of the immune response.

Authors:  Jordyn Feinstein; Bhama Ramkhelawon
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-09-14       Impact factor: 5.187

7.  Semaphorin3E/plexinD1 Axis in Asthma: What We Know So Far!

Authors:  Latifa Koussih; Abdelilah S Gounni
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Inflammation and its resolution as determinants of acute coronary syndromes.

Authors:  Peter Libby; Ira Tabas; Gabrielle Fredman; Edward A Fisher
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

9.  Syndecan-1 modulates the motility and resolution responses of macrophages.

Authors:  Julianty Angsana; Jiaxuan Chen; Sumona Smith; Jiantao Xiao; Jing Wen; Liying Liu; Carolyn A Haller; Elliot L Chaikof
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-12-30       Impact factor: 8.311

Review 10.  Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded "Cardiovascular Continuum".

Authors:  Peter Libby; Matthias Nahrendorf; Filip K Swirski
Journal:  J Am Coll Cardiol       Date:  2016-03-08       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.